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Abstract
Rationale Olfactory bulbectomy (OBX) in a laboratory
rodent leads to numerous behavioral deficits and involves
cognitive and motor changes that are used to model major
depression, but may also be a valuable tool in the study of
neurodegenerative disorders like Alzheimer’s disease.
Objectives This experiment evaluated the effects of
simvastatin, a cholesterol-lowering drug with putative
neuroprotective properties, on OBX-induced behavioral
changes.
Results Chronic administration of simvastatin, starting 48 h
after surgery, did not have any behavioral effect in OBX
rats, as tested in open field, passive avoidance and object-
recognition paradigms. In control rats, simvastatin treat-
ment resulted in an improved performance in both the
passive avoidance and the object-in-place task.
Conclusion In the present study, simvastatin treatment
enhanced cognition in intact rats, but had no effect in OBX
rats. These results are in line with the idea that statins may
attenuate (early) age-associated cognitive decline in humans.
Keywords Olfactory bulbectomy . Simvastatin .
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Introduction
Early-stage Alzheimer’s disease (AD) is associated with
marked impairments in olfactory function (Warner et al.
1986; Djordjevic et al. 2007), and neurofibrillary tangles
and neuritic plaques have been found in olfactory bulbs of
AD brains (Ohm and Braak 1987). In rodents, bilateral
olfactory bulbectomy (OBX) leads to extensive cognitive
impairments, with deficits in learning and memory
(Mucignat-Caretta et al. 2006; Kelly et al. 1997). These
behavioral deteriorations become apparent about 2 weeks
after ablation of the olfactory bulbs (Mucignat-Caretta et al.
2006), indicating an effect beyond the sensory deficit.
Indeed, it is established that anosmia does not account for
the major OBX-induced changes in cognitive and other
behaviors (Cain 1974; Van Riezen et al. 1977). Anatomi-
cally, neurons of the main and accessory olfactory bulbs
project to cortical, amygdala, and hippocampal regions. The
bulbectomy-induced behavioral deficits are probably
attributable to retrograde degeneration of these neurons
(Kelly et al. 1997; Song and Leonard 2005). Moreover,
neuronal damage following OBX is thought to be
enhanced by accompanying inflammatory reactions
(Myint et al. 2007; Song et al. 2009).
One of the most robust behavioral changes induced by
bulbectomy is locomotor hyperactivity in the open field
test, which could be normalized by chronic, but not acute,
administration of antidepressants (Breuer et al. 2007; Kelly
et al. 1997). Furthermore, OBX has been reported to
decrease hippocampal neurogenesis, a putative pathogenic
mechanism in depression (Koo et al. 2010) that could be
subsequently reversed by the antidepressant citalopram
(Jaako-Movits and Zharkovsky 2006).
In addition to its role in depression, hippocampal
degeneration has been suggested to be the basis, at least
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partly, for the cognitive deficits in AD (Thompson et al.
2004). Thereby, OBX was associated with increased levels
of beta-amyloid protein in neocortex and hippocampus
(Aleksandrova et al. 2004). Notably, drugs approved for
the treatment of AD were reported to alleviate cognitive
impairments induced by OBX, providing the model
pharmacological validation with respect to AD. In
particular, both cholinesterase inhibitors (Hozumi et al.
2003; Yamamoto et al. 2010) and the NMDA-receptor
antagonist memantine (Borre et al. 2010) improved
cognition in OBX rats. Thus, the OBX model may also
be useful for modeling (early) Alzheimer’s disease.
Up till now, no drug has been shown to completely
protect neurons from degradation in Alzheimer’s disease.
Statins or HMG-CoA reductase inhibitors were originally
designed to lower cholesterol, but may also have neuro-
protective and anti-inflammatory effects, and could be
beneficial for AD pathology (Kojro et al. 2001; Ostrowski
et al. 2007; Youssef et al. 2002). Thereby, statins could
have cognition-enhancing properties, as the lipophilic drug
simvastatin improved learning and memory in animal
models for AD and traumatic brain injury, respectively (Li
et al. 2006; Wu et al. 2008), and enhanced long-term
potentiation in hippocampal slices (Mans et al. 2010). In
addition, simvastatin stimulated hippocampal neurogenesis
and expression levels of the neurotrophic factors brain-
derived neurothropic factor (BDNF) and vascular endothe-
lial growth factor (VEGF) (Wu et al. 2008). Furthermore,
according to several epidemiological studies, statins may
reduce the risk of developing AD (Darvesh et al. 2004;
Sparks et al. 2005; Wolozin et al. 2000). Though, a more
recent meta-analysis (Zhou et al. 2007) found no preven-
tative effects of statins. However, in this study, no
difference was made between statins that pass the blood–
brain barrier and those that do not.
In the present study, we investigated the effects of
simvastatin treatment on learning and memory in OBX
and control rats. Simvastatin was administered chroni-
cally (25 days), starting 48 h after bulbectomy, and
followed by several behavioral tests (i.e., open field,




In total, 52 male Sprague–Dawley rats (Harlan, Zeist, The
Netherlands) were used in the experiments, weighing
approximately 330 g at the time of surgery. During surgery,
three animals died. Subjects were socially housed (three or
four per cage, either OBX or control animals), on a 12:12
light/dark cycle (lights on: 0600–1800 hours). Food and
water were available ad libitum, room temperature was 22–
24°C, and humidity between 30% and 60%. Animals were
allowed to acclimate to their surroundings for 2 weeks prior
to testing and handled daily except for the weekends. At the
end of the experiment, the animals were killed by
decapitation, and olfactory bulb ablation was verified.
Experiments were performed according to the Guide for
Care and Use of Laboratory Animals and were approved by
the Ethical Committee for Animal Research of Utrecht
University.
Olfactory bulbectomy
The surgical procedure was performed as previously
described (Breuer et al. 2007). Briefly, animals were
anesthetized (isofluorane 3–4%) and subsequently placed
in a stereotaxic instrument. Two burr holes were drilled on
either side of the skull, 2 mm in diameter. Tissue was
removed with a blunt hypodermic needle and a vacuum
pump. When all animals were awake and moving, they
were returned to their home cages and monitored closely
for 2 days. Subjects were randomly assigned to surgery or
control groups. No sham operations were performed, since
in previous experiments we have found that sham-operated
animals do not differ from non-operated control animals
(unpublished finding).
Experimental design
Upon arrival, 52 rats were randomly divided into four
groups (n=13). Both OBX and control animals were orally
(p.o.) treated with either simvastatin (10 mg/kg, suspended
in a vehicle containing 0.5% gelatin and 5% mannitol) or
vehicle only. Injections were applied daily between 9 and
11 a.m. for 25 days, starting 48 h after surgery. Behavioral
tests included the open field test (consecutively performed
pre-surgically, after 2 weeks of treatment, and 1 week post-
treatment), passive avoidance (habituation trials, 3 days
pre-surgery; acquisition trials, 2 days pre-surgery; retention
trials, 1 day pre-surgery, and 3 weeks post-surgery), and
object–place recognition tests (object–place and object-in-
place tests at treatment day 25 and 1 day post-treatment,
respectively, following habituation sessions on treatment




In an open-topped arena with light gray walls (72×72×
45 cm), locomotion was videotaped for 5 min. Luminance
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was 20 lux at floor level. Distance moved was analyzed
using Ethovision (Noldus, The Netherlands).
Passive avoidance
To study passive avoidance behavior, a one-trial, step-
through passive avoidance paradigm was used (adapted
from Van Riezen and Leonard 1990), where rats learn to
remain in an aversive environment in order to avoid
receiving a footshock. The test apparatus (49×23×35 cm,
l × w × h) consisted of a white, brightly lit (230 lux)
compartment (19×23×35 cm) and a black, dark compart-
ment (29×23×35 cm); connected by a sliding door (8×
6 cm). Rats were habituated to the apparatus and test
procedure 1 day prior to the acquisition trial. In the
habituation session, the subject was placed in the white
compartment and after 10 s, the door to the black
compartment was opened. After the animal stepped inside,
the door was closed and the subject was left in the black
compartment for 10 s without a shock being delivered.
During the acquisition trial, the animal was placed in the
white compartment, and 10 s later the door was opened. As
soon as the animal entered the black compartment, the door
was closed and a footshock of 0.6 mA was presented for
3 s, after which the animal was immediately returned to its
home cage. One day after the acquisition trial (and one day
before OBX surgery), the first retention trial was per-
formed, followed by a second retention trial 21 days post-
surgery. The latency time was defined as the time between
opening of the door and entrance of the animal into the
black compartment with all four paws. A cut-off time of
300 s was used. The animal was immediately taken out of
the apparatus and returned to its home cage after entering
the black compartment. No shock was delivered during
retention trials. Any subject that showed latencies shorter
than 60 s in the first retention trial was excluded from
analysis.
Object–place recognition
In this paradigm, the ability of rats to detect a mismatch
between a remembered and novel location of a familiar
object is evaluated (Dix and Aggleton 1999; Barker et al.
2007). Prior to the first test, animals were habituated to an
open-topped, rectangular arena (72×37.5×45 cm) with
objects different from those used in test trials, for 15–
20 min daily for three consecutive days. The procedure of
behavioral tasks consisted of an acquisition phase (3 min
for object–location task and 5 min for object-in-place task),
followed by a retention interval (5 min) and preference test
phase (3 min). Both objects and arena were thoroughly
cleaned with alcohol (70% v/v) after each sample and test
phase, in order to eliminate olfactory cues. Objects were
approximately 5×5×5 cm and made of ceramics, glass, or
plastic. Any animal that failed to reach a minimum of 5 s of
object exploration in the test phase was excluded from the
analysis.
The object–location task
This task assesses the rat’s ability to discriminate between
objects on familiar and novel locations. In the sample
phase, the animal was exposed to two objects placed in the
corners of the arena, 15 cm from the two nearest walls.
During the retention phase, one of the objects was left in
the original position while the other object was moved to a
novel location (i.e., near the corner adjacent to the original
position). The position of the displaced object (i.e., left or
right) was counterbalanced within and between groups.
The object-in-place task
In this topological task, the animal’s ability to recognize
spatial relationships between objects is evaluated. During
the sample phase, the animals were exposed to four
different objects, each placed near another corner in the
arena. Subsequently, the animals were allowed to explore
the objects for 5 min. In the test phase, two objects were
swapped. The position of the moved objects was counter-
balanced within and between groups.
Discrimination ratio
For both tasks, the discrimination ratio was calculated as
time spent exploring object(s) that changed position
compared to object(s) that remained in the same position
relative to the total time spent exploring all objects,
Fig. 1 Outline of all behavioral tests and interventions performed in
chronological order (the day of OBX surgery is day 1). For test
procedures, see text. Each animal was tested in all paradigms
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according to the formula: (t [novel]− t [constant]) /
(t [novel]+t [constant]). Exploratory behavior was defined
as orienting the nose towards the object at a distance <4 cm.
In behavioral scoring, the experimenter was blind to the
surgical and treatment status of the animal. Discrimination
performance during the first minute of testing is used for
analysis, as this has proven to be the most sensitive period
of object recognition (Dix and Aggleton 1999). Any animal
that failed to reach a minimum of 5 s of object exploration
in the test phase was excluded from analysis.
Statistical analysis
Total distances moved in the open field test were analyzed
using two-way ANOVA, followed by post hoc t tests with
Bonferonni correction. Assumptions of normality and
homogeneity of variance were tested with Kolmogorov–
Smirnov and Levene’s tests, respectively. Passive avoid-
ance latency times were analyzed using nonparametric
statistics (Kruskal–Wallis), followed by post hoc Dun’s
multiple comparison test and Mann–Whitney U test. Group
comparisons in object recognition tests were made by two-
way ANOVAs, and to discriminate if group performance
was significantly above chance level, one-sample t tests
were used. All differences were considered to be significant




OBX animals were significantly more active compared to
controls (two-way ANOVA, F [1, 45]=33.3, p<0.001; post
hoc corrected independent samples t tests, t [23]=−5.271, p=
0.000, t [22]=−3.153, p=0.01, for vehicle and simvastatin-
treated animals, respectively). Simvastatin did not affect
locomotion after 14 days of treatment (F [1, 45]=0.352, ns)
(Fig. 2). Two days post-treatment, a second open field test
was performed giving similar outcomes (data not shown).
Learning and memory
Passive avoidance Pretreatment and pre-surgery, mean
latency times to enter the black compartment did not differ
between groups (not shown). Twenty-one days following
surgery (and 18 days of simvastatin treatment), passive
avoidance memory differed significantly between groups
[Kruskal–Wallis, H (3)=26.49, p<0.0001]. Post hoc anal-
ysis revealed that for the two treatment conditions, OBX
groups were significantly different from controls (p<0.01),
and that there was no significant effect of treatment.
However, in measuring latency times, we used a cut-off
time of 300 s. This highest possible value was reached
by seven out of nine simvastatin-treated control animals,
while only two out of ten vehicle-treated controls
showed a latency time of 300 s (Fig. 3). Also, a single
comparison of simvastatin- vs. vehicle-treated controls
revealed a significant difference between the groups
(Mann–Whitney, U=22.0, p=0.047).
Object–place recognition
Object–location task Twenty-seven days after bulbectomy,
object–location recognition was significantly impaired in
OBX rats (two-way ANOVA, F [1, 41]=12.421, p=0.001)
and not affected by simvastatin in any group (F [1, 41]=
0.025, ns). Both control groups performed significantly
better than chance (i.e., a level of zero) (one sample t test, t
[10]=5.867, p=0.000 and t [11]=6.787, p=0.000 for statin



















Fig. 2 Simvastatin did not affect OBX-induced hyperactivity. Rats
received daily either simvastatin (10 mg/kg, p.o.) or vehicle for
14 days, starting 48 h post-surgery. Shown is mean+SEM of distance
traveled during the first 5 min of the open field test. Post hoc
comparisons vs. controls, ***p≤0.001, **p≤0.01. N=11–13



















Fig. 3 Passive avoidance behavior was significantly impaired
following OBX and improved by simvastatin in control animals only.
Shown is the mean + SEM of the latency time to enter the dark
compartment. Simvastatin (10 mg/kg, p.o.) was administered daily for
18 days. Post hoc comparisons vs. control groups, **p≤0.01;
comparison vs. vehicle treated control, # p<0.05. N=9–10
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and vehicle groups, respectively), whereas OBX animals
did not perform above chance (Fig. 4a).
Object-in-place task Twenty-eight days after surgery,
object-in-place recognition of OBX rats was significantly
inferior compared to controls (F [1, 41]=5.313, p=0.026),
which was not significantly altered by statin treatment (F
[1, 41]=1.262, ns). However, additional analysis revealed
that only the simvastatin-treated control group performed
significantly above chance level (t [9]=5.77, p<0.001)
(Fig. 4b).
Discussion
The present study shows that chronic treatment with
simvastatin (25 days) improves cognitive performance in
control rats, as observed in object-in-place recognition and
passive avoidance tasks. Furthermore, simvastatin did not
improve OBX-induced behavioral deficits (i.e., object–
place recognition, open field, and passive avoidance
behavior). Studies in rat and mouse models of Alzheimer’s
disease (Li et al. 2006) and traumatic brain injury (Wu et al.
2008) have shown that statins have neuro-restorative and
anti-inflammatory properties. This raises the question as to
why simvastatin proved to be ineffective in ameliorating
learning and memory in the OBX rat.
One suggestion is that the brain damage resulting from
ablation of the olfactory bulbs is too severe or extensive to
be counteracted by simvastatin treatment. In a study by
Skelin et al. (2008), it was shown that OBX leads to
reduced glucose utilization in 13 different brain areas,
which is indicative for a widespread reduction in brain
activity. Affected brain areas included the ventral hippo-
campus and the amygdala. In the abovementioned traumatic
brain injury study, which reported improved cognitive
performance following chronic simvastatin treatment (Wu
et al. 2008), the tissue damage was more restricted.
Specifically, neuronal cell death primarily occurred in the
boundary zone of the injured cortical region and the CA3
region of the hippocampus, which gave rise to spatial
learning deficits.
Alternative explanations why simvastatin might have
been ineffective in the OBX model could relate to dosage
and time factors. In the current study, simvastatin was
applied in a dose of 10 mg/kg. Elsewhere, doses ranging
from 1 to 50 mg/kg of simvastatin have been successfully
used (Lu et al. 2007; Wu et al. 2008, 2009). Therefore, it is
unlikely that our dose of 10 mg/kg was too low. Moreover,
the 10 mg/kg dose was effective in the control animals.
Since we started simvastatin treatment 48 h after OBX
surgery, it is possible that at this stage, part of the neurons
in brain areas beyond the olfactory bulbs had already been
damaged. Our previous telemetry studies demonstrated that
rat home-cage hyperactivity becomes apparent 2–3 days
after OBX surgery (Vinkers et al. 2009). Furthermore,
OBX-induced passive avoidance deficits have been
reported to develop between 24 h and 14 days after surgery
in mice (Hozumi et al. 2003). Taken together, it is likely
that although some brain tissue may have been irreversibly
damaged by the onset of treatment, there may still have
been room for improvement, e.g., limiting further loss of
neuronal function or even enhancing the function of
remaining neurons.
Based on a reversal of locomotor hyperactivity in the
open field test, the OBX model has been used to predict
known antidepressant drugs across laboratories (Breuer et
al. 2007; Kelly et al. 1997). In the present study, chronic
simvastatin treatment did not normalize the hyperactivity
response of OBX rats (Fig. 2). This was an unexpected
finding, as like antidepressants (Sahay and Hen 2007),
simvastatin stimulates neurogenesis (Wu et al. 2008) and
the production of the neurotrophic factors BDNF and





































Fig. 4 Simvastatin significantly improved object–place recognition
selectively for control animals. a Performance in object–location task
for control and OBX groups receiving either vehicle or simvastatin. N=
10–11. b Performance for each group in object-in-place task. N=10–12.
Simvastatin (10 mg/kg, p.o.) was administered daily for 25 days. Shown
is the mean+SEM of the discrimination ratio in the first minute of the
test phase. ***Denotes significant difference from chance (= 0) (one
sample t test, p≤0.001)
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VEGF in the hippocampus (Wu et al. 2008). Stimulation of
neurogenesis is considered necessary for the antidepressant
effects in mice (Santarelli et al. 2003). In addition, chronic
treatment with the anti-inflammatory drug celecoxib nor-
malized OBX-induced hyperactivity in rats (Myint et al.
2007; Song et al. 2009). Based on the studies supporting
anti-inflammatory properties of statins, we hypothesized
that simvastatin would do the same. On the other hand, to
the best of our knowledge, no antidepressant effects of
statins have been reported in humans so far.
Although we did not find any effect of simvastatin in
OBX rats, the drug enhanced behavioral performance in
controls. In the beginning of the experiment, all animals
went through a passive avoidance acquisition trial, in which
they received a shock (0.6 mA, 3 s). Theoretically, this
could have interfered with later task performance, for
instance by increasing anxiety. This may be in particular
true for the control group, since OBX animals do not recall
memories acquired before surgery (see Fig. 3). The
remaining question is whether the effects of simvastatin in
control animals can be ascribed to enhanced cognition, or
are just the result of decreased anxiety states.
In one study, using the same dose of simvastatin as we
did, anxiolytic effects of the drug were reported in rats
(Wang et al. 2009). Based on the present findings, it cannot
be excluded that possible anxiolytic effects of simvastatin
might have played a role in improving performance in the
object-in-place task. However, the possible contribution of
this effect is considered small, since the drug also increased
latency times in the passive avoidance test—a procedure
widely used in memory research (Gold 1986). Furthermore,
a number of studies report statin-induced improved cogni-
tion in control mice (Li et al. 2006), possibly by modulation
of signaling pathways implicated in synaptic plasticity and
(spatial) memory formation (Laufs et al. 1998; Vaughan
2003). Notably, increased levels of NMDA receptors
following chronic simvastatin treatment have been reported
in rats (Wang et al. 2009). NMDA receptors play an
important role in learning and memory (Magnusson and
Cotman 1993).
All tests performed in this study are considered to be
dependent on the hippocampus, though depending on the
task, cortical brain areas may be involved as well (Barker et
al. 2007; Burwell et al. 2004). Both, the object-in-place
recognition and passive avoidance tests—where simvastatin
was found to exert beneficial effects—are more complex
tasks. In the passive avoidance task, contextual fear
learning is evaluated, i.e., the animal has to make an
association between the context and an aversive stimulus.
Burwell et al. (2004) reported that passive avoidance
learning requires an intact corticohippocampal circuit (i.e.,
hippocampus and perirhinal, postrhinal, and enthorhinal
cortices). Also, in a lesion study by Barker et al. (2007), it
was shown that the object-in-place task is dependent on an
intact medial prefrontal and perirhinal cortex, while the
object–location task was not affected by lesions in these
areas.
Based on these findings, it can be hypothesized that
simvastatin exerts cognition-enhancing effects in tasks that
require cortical participation. On the other hand, it is also
reported that simvastatin improves spatial learning in the
Morris water maze (Li et al. 2006), which is thought to
depend on an intact hippocampus (Burwell et al. 2004;
Moses et al. 2005). However, as suggested by Burwell et al.
(2004), the complexity of spatial cues present during the
Morris water maze test may determine whether cortical
regions become involved or not. Thus, mechanisms
underlying cognition-enhancing effects of simvastatin re-
main to be determined. Unraveling those mechanisms may
be of particular importance, as in non-demented elderly,
statins have been reported to improve cognition (Parale et
al. 2006) and to reduce the rate of cognitive decline
(Bernick et al. 2005; Sparks et al. 2010).
In conclusion, we show here that simvastatin treat-
ment has beneficial effects on higher-order learning and
memory in intact rats, but is without any (behavioral)
effect in OBX rats. Based on the present findings, we
present two suggestions which could explain why
simvastatin was ineffective in restoring behavioral defi-
cits induced by bulbectomy. First, it may be that the
OBX-induced neuronal damage was too severe to be
counteracted by simvastatin treatment. Second, simvasta-
tin may only improve higher-order cognition that
requires cortical participation, while in OBX animals
(task-relevant), subcortical brain areas are also affected.
Finally, the finding that simvastatin improves learning
and memory in control rats, supports the view that statins
may prevent or improve (early) age-associated cognitive
decline in elderly humans.
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